This integrated approach may help to select SCLC patients that would benefit most from single agent use of drugs such as HDAC [22] and PLK [23] inhibitors that are broadly effective across SCLC cell lines but demonstrate limited activity in clinical trials. This evidence concerns the gene PLK1 and small cell lung carcinoma.